Darren R. Feldman, MD
Chair, Quality Assurance, Department of Medicine
Genitorinary Malignancies; Testicular Cancer (Germ Cell Tumors); Kidney Cancer (Renal Cell Carcinoma)
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Feldman accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, University of Maryland School of Medicine
Internal Medicine - New York University School of Medicine; Chief Resident, Department of Medicine - Memorial Sloan Kettering Cancer Center
Oncology/Hematology - Memorial Sloan Kettering Cancer Center
Medical Oncology; Hematology
I am a medical oncologist who cares for people with genitourinary cancer. I specialize in treating testicular cancer (germ cell tumors) and kidney cancer (renal cell carcinoma). My research centers on developing new drugs or drug combinations for people with these cancers. I also lead national and international clinical trials for people with genitourinary cancer.
I became interested in cancer care at a very young age. My father is a medical oncologist. He took me on rounds with him when I was in high school and I appreciated the close relationships that oncologists develop with their patients. I was also drawn to the fascinating biology of how cancers form and progress. My career choice was solidified after being exposed to the leading-edge research and patient care at MSK while spending part of my residency and completing my fellowship here.
When I meet with people who have recently been diagnosed with cancer, my goal is to help them feel informed about their disease and treatment options. I want them to be confident that they are going to get the best care possible. I reassure them by discussing our vast experience with treating their illness and preventing and addressing treatment-related side effects. Studies have shown that people whose cancer is treated at an experienced cancer center like MSK achieve better outcomes than those treated at less specialized institutions. I am proud to be among the most experienced doctors caring for people with testicular cancer and kidney cancer. Equally as important, I treat my patients with compassion and respect, just as I would want my own family to be treated.
People with kidney cancer are now benefitting from advances made during the last 15 years, many led by researchers at MSK. We now have more treatment options than ever to help control the disease. Immunotherapy and targeted therapies combined with immunotherapy are producing unprecedented response rates and survival outcomes. My research in this area is examining the integration of PET imaging and radiolabeled targeted therapies for people with clear cell renal cancer, which has shown resistance to standard treatments. I am also working to better understand non-clear cell renal cancer, which is less common.
I direct MSK’s testicular cancer research program, which addresses all aspects and stages of the disease. We are testing various therapies and the effectiveness of treatment combinations, including immunotherapy and targeted therapies. In fact, we are one of the only institutions in the world conducting studies to understand why some people develop germ cell tumors. We are also assessing the biologic basis for why some of these cancers are resistant to chemotherapy.
I also collaborate with the laboratory of David Solit. My colleagues and I are working to identify the molecular features of testicular cancer that could predict sensitivity or resistance to chemotherapy and overall patient outcomes. In addition, I concentrate on characterizing and preventing the long-term side effects of treatment for testicular cancer, such as heart disease, metabolic syndrome, and other cancers.
I have presented my research and lectured at meetings throughout the United States and in other countries.
Outside of work, I enjoy spending time with my wife and daughter, learning languages, reading mystery novels, and playing golf.
I treat my patients with compassion and respect, just as I would want my own family to be treated.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2014, 2016-2020)
- John Mendelsohn Housestaff Teaching Award, Department of Medicine, Memorial Sloan Kettering Cancer Center (2005-2006)
- Clinical Trials Investigated by Dr. Feldman
- A Phase II Study of Nivolumab Immunotherapy in Combination with 177Lu-Girentuximab for Advanced Kidney Cancer
- A Phase III Study Comparing Conventional-Dose Chemotherapy with High-Dose Chemotherapy for Persistent or Recurrent Germ Cell Tumors
- A Phase III Study of Accelerated versus Standard Chemotherapy for Patients with Intermediate- and Poor-Risk Metastatic Germ Cell Tumors
- Clinical Trials Co-Investigated by Dr. Feldman
- A Phase II Study of Nivolumab Immunotherapy plus Cabozantinib in Patients with Non-Clear Cell Renal Cell Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Paclitaxel, ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors. J Clin Oncol. 2016 Jul 20;34(21):2478-83.
Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2016 Nov;34(32):3846-3853.
Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol. 2016 Nov;34(33):4000-4007.
Visit PubMed for a full listing of Dr. Feldman’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Darren R. Feldman discloses the following relationships and financial interests:
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.